Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154462 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154418 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL30295961 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL29478950 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL19785503 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL25094875 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154556 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL20807077 | 0.93 | PTPN11 (0.87) | PTPN11KCNH2EGFR | |
| SCHEMBL24233670 | 0.91 | PTPN11 (0.84) | PTPN11KCNH2EGFR | |
| SCHEMBL20807079 | 0.91 | PTPN11 (0.83) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1018 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2026-05-28 | — | — | US | claimed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | claimed |
| WO-2026101937-A1 | COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF | ATOSSA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20250262194-A1 | PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-21 | — | — | US | claimed |
| EP-4601649-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| US-12377101-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-08-05 | — | — | US | claimed |
| US-20250228938-A1 | THE COMBINATION OF MACROPHAGE-DIRECTED IMMUNOTHERAPY AND TARGETED AGENTS FOR TREATMENT OF CANCER | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2025-07-17 | — | — | US | claimed |
| US-20250228834-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | HEPAREGENIX GMBH (DE) | 2025-07-17 | — | — | US | claimed |
| US-20250177389-A1 | METHOD OF TREATMENT INCLUDING KRAS G12C INHIBITORS AND SHP2 INHIBITORS | ELI LILLY AND COMPANY | 2025-06-05 | — | — | US | claimed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | claimed |
| WO-2022226145-A1 | METHOD AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS | HOSPITAL RHODE ISLAND (US) | 2022-10-27 | — | — | WO | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2022103834-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| CN-114437065-A | Heterocyclic compounds, their preparation and use | 益方生物科技(上海)股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | claimed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | claimed |
| US-20220079947-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-03-17 | — | — | US | claimed |
| US-20220062260-A1 | COMBINATION THERAPY FOR TREATMENT OF LKB1 DEFICIENT CANCERS | NEW YORK UNIVERSITY | 2022-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228834-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | KRAS, MAPK4, NRAS | PTPN11 66/4885KCNH2 3984/4885EGFR 161/4885 |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | PDCD1, CD274, PTPN1 | PTPN11 17/4885KCNH2 2775/4885EGFR 250/4885 |
| US-20250262194-A1 | PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER | KRAS, NRAS, TP53 | PTPN11 27/4885KCNH2 4220/4885EGFR 130/4885 |
| US-20220079947-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | PTPN11 9/4885KCNH2 4389/4885EGFR 234/4885 |
| US-12377101-B2 | Combination therapies | KRAS, NRAS, HRAS | PTPN11 9/4885KCNH2 4389/4885EGFR 234/4885 |
| US-20250177389-A1 | METHOD OF TREATMENT INCLUDING KRAS G12C INHIBITORS AND SHP2 INHIBITORS | KRAS, NRAS, HRAS | PTPN11 12/4885KCNH2 3088/4885EGFR 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.